Calrubrutinib Improves Outcomes in DLBCL Before Chemotherapy
- Acalabrutinib (Calquence), a targeted therapy, shows promise as a first-line treatment for mantle cell lymphoma, perhaps reducing the need for conventional chemotherapy (like R-CHOP).
- * Drug: Acalabrutinib (Calquence) - made by AstraZeneca * Condition: Mantle cell lymphoma * Treatment Approach: Monotherapy (acalabrutinib alone) before chemotherapy.
- Hill (Cleveland Clinic Cancer Institute) believes the findings, combined with other research presented at ASH, suggest a future where more targeted therapies are used, especially for patients who...
Here’s a breakdown of the key details from the provided text:
main Point:
Acalabrutinib (Calquence), a targeted therapy, shows promise as a first-line treatment for mantle cell lymphoma, perhaps reducing the need for conventional chemotherapy (like R-CHOP). It demonstrated “excellent” outcomes and tolerability in a study assessing lymph node regression.
Key Details:
* Drug: Acalabrutinib (Calquence) – made by AstraZeneca
* Condition: Mantle cell lymphoma
* Treatment Approach: Monotherapy (acalabrutinib alone) before chemotherapy.
* Findings: Lymph node regression was assessed, and outcomes/tolerability were “overall excellent.”
* Potential Benefits: Could be particularly useful for:
* older patients
* Patients not suitable for R-CHOP chemotherapy
* Potentially all patients, allowing for less toxic, more targeted treatment.
Expert Opinion:
Dr. Brian T. Hill (Cleveland Clinic Cancer Institute) believes the findings, combined with other research presented at ASH, suggest a future where more targeted therapies are used, especially for patients who may not tolerate or benefit from traditional chemotherapy.
source Information:
* Source: healio Interviews
* Reference: Roschewski M, et al. Abstract 56. Presented at: ASH Annual Meeting and Exposition; Dec. 6-9, 2025; Orlando.
* Disclosure: Dr. Hill has financial relationships with several pharmaceutical companies (AbbVie, AstraZeneca, BMS, Genentech, and Genmab Medicines).
Additional Information:
* The article promotes Healio AI, a tool for accessing clinical information.